This is a working overview of bioavailability, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-16 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Consumer sentiment began to turn after Five Guys prices began increasing in the 2020s, with locations raising prices by as much as 40% between 2021 and 2022, with the cost of a burger, fries, and a drink cresting at $20. A 2024 survey of large chains ranked Five Guys as the second-most expensive fast food hamburger restaurant in the country behind Shake Shack.
==== Liver ==== (help wikipedia by contributing to this subsection) Glycogenosis-like phenotype of congenital hyperinsulinism due to HNF4A mutation or MODY1 (maturity-onset diabetes of the young, type 1). This phenotype of MODY1 has macrosomia and infantile-onset hyperinsulinemic hypoglycemia, physiological 3-OH butyrate, increased triglyceride serum levels, increased level of glycogen in liver and erythrocytes, increased liver transaminases, transient hepatomegaly, renal Fanconi syndrome, and later develop liver cirrhosis, decreased succinate-dependent respiration (mitochondrial dysfunction), rickets, nephrocalcinosis, chronic kidney disease, and diabetes.
As late as the 1960s, the element was also referred to simply as emanation. The first synthesized compound of radon, radon fluoride, was obtained in 1962. Even today, the word radon may refer to either the element or its isotope 222Rn, with thoron remaining in use as a short name for 220Rn to stem this ambiguity. The name actinon for 219Rn is rarely encountered today, probably due to the short half-life of that isotope. The danger of high exposure to radon in mines, where exposures can reach 1,000,000 Bq/m3, has long been known. In 1530, Paracelsus described a wasting disease of miners, the mala metallorum, and Georg Agricola recommended ventilation in mines to avoid this mountain sickness (Bergsucht). In 1879, this condition was identified as lung cancer by Harting and Hesse in their investigation of miners from Schneeberg, Germany. The first major studies with radon and health occurred in the context of uranium mining in the Joachimsthal region of Bohemia. In the US, studies and mitigation only followed decades of health effects on uranium miners of the Southwestern US employed during the early Cold War; standards were not implemented until 1971. In the early 20th century in the US, gold contaminated with the radon daughter 210Pb entered the precious metal supply chain of that country's jewelry industry. Gold brachytherapy seeds that had held 222Rn were illicitly or unknowingly sold and melted down. The presence of radon in indoor air was documented as early as 1950.
Sources: en.wikipedia.org
=== Laboratory automation development === Markin's interest in laboratory automation, blending clinical processes with information technology, began during his graduate studies, which focused on graph theory. By 1989, he developed a prototype system that would later allow "plug-and-play" integration of automation systems and clinical analyzers for managing and testing of patient specimens. His approach was to build an automated transport system which would allow various testing processes using commercial, off-the-shelf testing and collection systems. He didn't design the instruments, but sought an automated system to manage the testing processes, leading to increased efficiency, improved reporting and lower laboratory costs. He founded LAB-InterLink in 1993, and commercialized a system to manage clinical specimens using an automated transportation system and specimen processing devices (i.e. decapping devices, recapping devices, instrument or analyzer interfaces, etc.) for laboratory testing and processing. For example, the specimen would be separated using a centrifuge; the specimen container would be uncapped; the specimen would be tested as ordered by the physician; the container would be recapped; and the specimen would be stored in the event further testing is needed. Test results were provided to the physician or provider as part of the software management system. LAB-InterLink sold automation systems in North America and internationally, and offices were set up in the United States, Canada and Israel. In 2004, the U.S.
Nalbuphine, sold under the brand names Nubain among others, is an opioid analgesic which is used in the treatment of pain. It is given by injection into a vein, muscle, or fat. Side effects of nalbuphine include sedation, sweatiness, clamminess, nausea, vomiting, dizziness, vertigo, dry mouth, and headache. Unlike other opioids, it has little to no capacity to cause euphoria or respiratory depression. There is also little to no incidence of dysphoria, dissociation, hallucinations, and related side effects at typical therapeutic doses. Nalbuphine is a mixed agonist/antagonist opioid modulator. Specifically, it acts as a moderate-efficacy partial agonist or antagonist of the μ-opioid receptor (MOR) and as a high-efficacy partial agonist of the κ-opioid receptor (KOR), whereas it has relatively low affinity for the δ-opioid receptor (DOR) and sigma receptors. Nalbuphine was patented in 1968 and was introduced for medical use in the United States in 1979. It is marketed in many countries throughout the world.
Transporter competition: Many GalNAc-conjugated siRNA drugs (e.g., inclisiran, givosiran, lumasiran) are taken up by hepatocytes via the asialoglycoprotein receptor (ASGPR). Co-administration of agents that saturate or alter this receptor pathway may affect hepatic delivery of the siRNA payload. Carrier protein binding: Some oligonucleotide drugs bind serum albumin or lipoproteins. Competition with highly protein-bound small molecules could alter free-drug concentrations. Indirect CYP modulation: siRNA drugs that silence transcription factors controlling CYP gene expression (e.g., silencing of PCSK9 influences LXR/SREBP pathways) may indirectly alter CYP expression in co-treated patients. On-target miRNA network perturbation: Because endogenous microRNA (miRNA) regulates the expression of drug-metabolizing enzymes and transporters, therapeutic oligonucleotides that modulate miRNA activity can produce secondary DDIs via altered enzyme expression rather than direct enzyme binding.
== Career == LeBlanc began his academic career in 1989 at North Carolina State University, where he became a professor of Toxicology and Environmental Health. He also served as an adjunct professor from 2012 to 2016 in the Department of Biological Sciences at Clemson University in South Carolina.
Sources: en.wikipedia.org
It was first synthesised in 1811 by Pierre Louis Dulong, who lost three fingers and an eye to its explosive tendencies. As a dilute gas it is less dangerous and is thus used industrially to bleach and sterilise flour. Nitrogen tribromide (NBr3), first prepared in 1975, is a deep red, temperature-sensitive, volatile solid that is explosive even at −100 °C. Nitrogen triiodide (NI3) is still more unstable and was only prepared in 1990. Its adduct with ammonia, which was known earlier, is very shock-sensitive: it can be set off by the touch of a feather, shifting air currents, or even alpha particles. For this reason, small amounts of nitrogen triiodide are sometimes synthesised as a demonstration to high school chemistry students or as an act of "chemical magic". Chlorine azide (ClN3) and bromine azide (BrN3) are extremely sensitive and explosive. Two series of nitrogen oxohalides are known: the nitrosyl halides (XNO) and the nitryl halides (XNO2). The first is very reactive gases that can be made by directly halogenating nitrous oxide. Nitrosyl fluoride (NOF) is colourless and a vigorous fluorinating agent. Nitrosyl chloride (NOCl) behaves in much the same way and has often been used as an ionising solvent. Nitrosyl bromide (NOBr) is red. The reactions of the nitryl halides are mostly similar: nitryl fluoride (FNO2) and nitryl chloride (ClNO2) are likewise reactive gases and vigorous halogenating agents.
On August 10, 2022, Brian José Infante Machín, President of the Masonic Union for the Freedom of Cuba, published a Facebook post on the account of the Ibero-American-European Alliance against Communism, calling for a national strike on Fidel Castro's birthday, August 13. He told Freemasons that they should march in the streets in solidarity with those young people who had been mistreated by the government during the July 11th Protests. In September 2022, according to the 2022 edition of La Gran Logia (the magazine of the Grand Lodge of Cuba), the Supreme Court of Masonic Justice either expelled or ratified the expulsion of seven Freemasons from the fraternity in Cuba; Pavel Guillén Guzmán from Dos Ríos Lodge in Palma Soriano, Pedro Demesio Martínez González from Astrea Lodge in Centro Habana, Luis Alberto Reyes Expósito from Asilo de la Virtud Lodge in Cienfuegos, Brian José Infante Machín from Luz Caballero Lodge No. 81 in Marianao, Lester Damián Cañizares from Luz Caballero Lodge No. 81, and Manuel Arístides Suárez Álvarez from Victor Hugo Lodge in Matanzas.
==== Specialty selection ==== Specialties differ in length of training, availability of residencies, and options. Specialist residency programs require participation for completion ranging from three years for family medicine to seven years for neurosurgery. This time does not include any fellowship that may be required to be completed after residency to further sub-specialize. In regard to options, specialty residency programs can range nationally from over 700 (family medicine) and over 580 (internal medicine) to 33 programs for integrated thoracic surgery and 28 programs for osteopathic neuromusculoskeletal medicine. Residents choose the teaching hospital where they want to perform their residency based upon many factors, including the medical specialties offered by the hospital and reputation and credentials of the hospital. The following table shows medical specialties and the residency training times for medical specialties, as reported by the American Medical Association in 2021.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.